Modern Aesthetics to Inspire Every Beautiful Moment
Hugel Aesthetics is working to bring our top-performing portfolio of aesthetic injectables to patients and practitioners around the world—and helping everyone achieve their aesthetic aspirations.
Hugel Seeks To Spark Joy With Everyone We Meet
As a leader in the South Korean aesthetics market since 2016, our approach is one built on innovation, efficiency, and joy. We are excited by the never-ending potential of our beauty journey together, and we strive to make the process easy and simple.
let’s stay in touch
Sign up to learn about the latest Hugel Aesthetics news and events.
Modern Aesthetics For a Modern World
Hugel sits at the intersection of beauty and technology, and we believe that the future of aesthetics is one that’s both inclusive and accessible. Our products are designed and manufactured to meet or exceed all relevant quality standards, and have been trusted by millions of faces around the world.
PRESS RELEASES
March 4, 2024
Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown)
lines in adults.
November 28, 2022
Hugel Aesthetics announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults.
October 25, 2022
Hugel Aesthetics announced the acceptance of its Biologics License Application for letibotulinumtoxinA, by the U.S. Food and Drug Administration (“FDA”).
October 6, 2022
Hugel Aesthetics announced that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for letibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines.
October 5, 2022
Hugel Aesthetics announced a presentation at the ASDS annual meeting highlighting data from its phase 3 clinical trial, BLESS III, assessing the efficacy of letibotulinumtoxinA in improving the psychosocial health-related QoL of subjects with moderate to severe glabellar lines.
July 27, 2022
III clinical trial in the Aesthetic Surgery Journal. The published data comes as Hugel is accelerating its efforts towards becoming a leading global medical aesthetics company.
June 23, 2022
Croma Aesthetics Canada Ltd., doing business as Hugel Aesthetics, today announced it received a Notice of Compliance from Health Canada for Letybo (letibotulinumtoxinA for injection) for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity (frown lines between the eyebrows) in adult patients under 65 years of age.
May 24, 2022
Hugel Inc. announced to convene an extraordinary general shareholders’ meeting to appoint Brent Saunders to the Board as a non-executive director.
January 27, 2022
Hugel America, Inc., a growth-focused joint venture between aesthetic market-leading partners Hugel Inc., and Croma-Pharma GmbH (Croma), announced that Croma has completed the decentralized procedure in Europe for Letybo® (LetibotulinumtoxinA for Injection) to treat glabellar (frown) lines.